

ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

One-pot synthesis of doxorubicin-loaded multiresponsive nanogels based on hyperbranched polyglycerol

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,
Accepted 00th January 2012Ana Sousa-Herves,^a Stefanie Wedepohl,^a and Marcelo Calderón^{a*}

DOI: 10.1039/x0xx00000x

www.rsc.org/


Doxorubicin-loaded nanogels with multiresponsive properties are prepared using hyperbranched polyglycerol as a biocompatible scaffold. The nanogels are synthesized in a single step combining free-radical polymerization and a mild nanoprecipitation technique. The nanogels respond to different biological stimuli such as low pH and reductive environments, resulting in a more efficient cell proliferation inhibition in A459 cells.

Recent advances in nanomedicine have prompted the need to develop delivery systems that can encapsulate a variety of novel therapeutics. The ideal drug delivery system should be biodegradable and biocompatible, target only the desired cells and tissue, and release their cargo at the intracellular space.^{1,2} Moreover, these nanocarriers should be smart so that they can deliver their payload at a well-defined time, place, or after a specific stimulus.^{3,4} Selected examples of biological stimuli include pH, temperature, and redox microenvironments.^{3,5} pH-sensitiveness can be exploited for selective drug release at the slightly acidic pH of tumors and/or at the more acidic cellular compartments endosome/lysosome. Complementary, redox sensitivity can trigger the cytosolic release of drugs due to the different concentrations of glutathione (GSH) in extracellular and intracellular compartments.

Among the different nanostructures employed in drug delivery, polymeric nanogels (NGs) have recently attracted a great deal of attention.⁶⁻¹⁰ NGs are a type of crosslinked, nanometric-sized hydrogel particles. They have a tunable size and a large surface area for multivalent bioconjugation and can incorporate therapeutics in their interior network. The entrapment of bioactive molecules (including anticancer drugs, proteins, and nucleic acids) in NGs as well as their *in vitro* release has been extensively investigated.⁶⁻¹⁰ The advantages of NGs over other drug delivery systems include their large water content, soft nature, high loading capacity, and stability of the resulting dispersion. Moreover, NGs can be engineered to provide optimal loading and release of drugs. In this context, the groups of Haag and Calderón have recently reported the preparation of NGs using hyperbranched polyglycerol (hPG) as a biocompatible, multifunctional scaffold.¹¹⁻¹³ It is noteworthy that hPG^{14,15} has been shown to be even less cytotoxic than the structurally similar and FDA-approved polyethylene glycol.^{16,17} Although there are several reports on smart NGs,^{4,18,19} the

preparation of multi-stimuli responsive NGs loaded with anticancer drugs^{11,20,21} is usually relatively complex and requires high shear stress (such as ultrasonication or high-pressure homogenization used in miniemulsion), multiple purification steps, and encapsulation of the drug after NG formation.²²

Herein, we present an efficient one-pot approach for preparing multiresponsive NGs that have been loaded with the anticancer drug doxorubicin (DOX) and employ hPG as a biocompatible scaffold. We have incorporated a pH-sensitive-monomer and a redox-responsive crosslinker into the NGs structure to give them stimuli-responsive properties. The NGs have been synthesized by free radical polymerization in combination with a nanoprecipitation²³ technique to template NG formation during the polymerization process (Scheme 1). To the best of our knowledge, this is the first example of NG preparation by nanoprecipitation employing free radical polymerization.



Scheme 1. Preparation of multiresponsive NGs and proposed mechanism of action.

First the bulk hydrogels were prepared in order to check the chemical compatibility and suitability of the system. The success of macrogel formation encouraged us to synthesize the gels with sizes in the nanometer scale. Unloaded NGs were prepared first in order to establish the synthetic conditions and to optimize the desired multiresponsive properties. Monomethyl oligo(ethylene glycol) acrylate (OEGA) and pH-responsive 2-(5,5-dimethyl-1,3-dioxan-2-yloxy)ethyl acrylate DMDEA^{20, 24} were selected as monomers. Redox-responsive bis(2-methacryloyl)oxyethyl disulfide (BMADS) was employed as the crosslinker while acrylated hPG (hPG-Ac, 35% functionalization) was chosen as a macro-crosslinker (Scheme 1). NGs were synthesized by free radical polymerization using a nanoprecipitation approach to template gel formation. The nanoprecipitation method involves particle formation by injection of the monomers and crosslinker solution into a non-solvent, and a simultaneous formation of a colloidal suspension caused by diffusion of the solvent into the non-solvent.²³ This technique has been traditionally employed for the preparation of nanoparticles from previously synthesized polymers, in particular from poly(lactic acid) and its copolymers. More recently, we and others have exploited inverse nanoprecipitation in water/acetone^{11, 12} and thermally nanoprecipitation¹³ for the preparation of NGs via chemical crosslinking of preformed polymeric scaffolds. In this work, nanoprecipitation was employed for the first time to prepare NGs comprising chain-growth polymerization.

Therefore hPG was highly functionalized with acrylate groups in order to obtain a derivative with similar solubility to hydrophobic DMDEA and BMADS. DMF was employed as the solvent and an aqueous solution of phosphate buffer (PB, 50 mM pH 8) as the non-solvent. Sodium dodecyl sulfate (SDS) was used as surfactant and AIBN as the organo-soluble initiator for the radical polymerization. The monomers, crosslinkers, and initiator were dissolved in DMF and subsequently precipitated into the non-solvent. The oxygen was then removed and the reaction temperature was increased to 65 °C to start the polymerization. The resulting NGs were extensively purified by dialysis in PB 10 mM pH 8 and stored at 4 °C. Detailed synthetic conditions are described in the Electronic Supplementary Information (ESI).

Several synthetic parameters were screened in order to obtain a suitable system for biological applications, i.e., with an adequate size, stability and low polydispersity (PDI). As a result, DMF and MeOH were tested as the solvent, whereby DMF turned out to be more suitable (in terms of particle size and stability) in a solvent/non-solvent ratio of 1:20. The influence of monomers and crosslinkers concentration as well as the monomer's feed-ratio in the NGs sizes was also studied (Table S1, ESI). Interestingly, raising the hPG concentration from 12.5% to 25% (weight %) only resulted in a small increase in the NG's size from 87 to 97 nm, as measured by dynamic light scattering (DLS). More importantly, employing the synthetic conditions reported in this work, NGs could not be obtained when hPG was not present. This suggests that the role of the hyperbranched macromolecule in the nanoprecipitation process is very important. In addition, a significant increase in the NG's size (87 vs. 176 nm, by DLS) could be observed when the ratio between hydrophobic DMDEA and hydrophilic OEGA was increased. NG 3 in Table S1 was selected as the optimal NG formulation because of its higher concentration and appropriate size. As shown in Fig. 1a, DLS measurements for NG 3 revealed a hydrodynamic size of ca. 87 nm and a low PDI (0.11). Atomic force microscopy (AFM) demonstrated the presence of spherical, uniformly distributed particles with a mean diameter of 45 nm (Fig. 1b). The smaller value observed in AFM can be attributed to the partial deswelling of the particles on the mica surface, as previously reported for other hydrophilic NGs.^{13, 25}




Fig. 1. (a) DLS intensity size distribution and (b) AFM of NG 3.

The progress of free radical polymerization could be easily monitored by the disappearance of the acrylate and methacrylate peaks (5.5-6.5 ppm) and the appearance of the peaks corresponding to the polymeric backbone in the ¹H NMR spectrum (Fig. 2). The OEGA peaks could be observed by NMR, which confirmed that OEGA did not diffuse to the aqueous phase during the polymerization. The hPG peaks could not be clearly seen because they overlapped with those of DMDEA and OEGA, but their presence within the NG is ensured by the fact that NGs do not form if hPG is not included in the formulation. As a comparison, ¹H NMR spectrum of NG 5 (lacking DMDEA monomer) is included in the ESI (Fig. S1). In addition, FT-IR spectroscopy of the freeze-dried NGs supported the lack of acrylate groups in the NGs (Fig. S2, ESI).




Fig. 2. ¹H NMR spectra (CDCl₃) of NG 3 and individual monomers and crosslinkers.

The multiresponsive behavior of the NGs was studied by DLS and AFM. Lowering the pH from 8 to 5 resulted in a huge increase in the size of NG 3 (from 87 to 200 nm), due to hydrolysis of the orthoester groups in DMDEA units, which led to more hydrophilic moieties and prompted the swelling of the NGs (Fig. 3a). The PDI of the hydrolyzed NGs was, nevertheless, quite low (0.16), probably because the hydrolysis of one of the monomers did not affect the integrity of the crosslinked polymeric network. AFM images of the hydrolyzed NGs further confirmed the increase in the mean size (166

nm, Fig. 3a). Notably, such an effect was not observed for the control NG 5, which lacks DMDEA monomer. In addition, the disappearance of the peak at 5.5 ppm in the ^1H NMR, which corresponds to the orthoester group, proved the hydrolysis of the NGs.

Similarly, the presence of the reductive agent dithiothreitol (DTT) produced an important increase in the sizes and PDI of the NGs (183 nm, PDI 0.26, Fig. 3b), which can be attributed to reduction-cleavage of one of the crosslinkers' disulfide bonds. In this case, the higher PDI values arose from the destabilization of the polymeric network. It is important to note that NGs did not completely decompose because the presence of the macro-crosslinker hPG preserves part of the polymeric network. This feature (high increase in size and PDI) can be exploited to achieve post-endocytic nanogel destabilization and drug release, due to the large intra/extracellular redox gradient present in most cells. Again, control NG 7, which lacked BMADS, did not show any sign of destabilization when treated under identical circumstances. Remarkably, the combination of OEGA with more hydrophobic monomers is known to present thermoresponsive properties, and has been employed by several groups for the preparation of thermosensitive nanogels.^{20, 26} Indeed, we observed an aggregation behavior for the NGs by DLS (presence of particles >1000 nm) when the temperature was increased from 25 to 55 °C. This process was completely reversible and the aggregates disappeared when the temperature was lowered back to 25 °C. Unfortunately, the cloud point for the NGs could not be obtained by typical turbidity experiments at different temperatures. In order to deeply investigate the sensitivity of NG 3 towards temperature, we employed nanoparticle tracking analysis (NTA). NTA was performed in high diluted solutions (0.01-0.001 mg/mL), which at the same time confirmed the stability of the NGs upon dilution, an important fact when intravenous applications are considered. NTA measurements showed that the number of particles decreased by 40 % when temperature was increased from 25 to 55 °C (from $3.62 \cdot 10^8$ particles/mL to $2.23 \cdot 10^8$ particles/mL), however, the main size of the particles remained in the same size range (101 and 109 nm, respectively). Taking into account the information obtained by DLS and NTA, we hypothesize that the NGs rapidly shrink when the temperature reaches a certain value, which leads to a reversible aggregation of the resulting smaller particles.




Fig. 3. (a) Intensity size distribution of NG 3 at pH 8 and at pH 5. AFM image of a hydrolyzed NG ($3.8 \times 3.8 \mu\text{m}$). (b) Intensity size distribution of NG 3 (w/o DTT) and in the presence of 20 mM DTT.

With a reliable and simple method for the preparation of multiresponsive NGs in hand, we decided to go a step further and incorporate the anticancer drug DOX during NG synthesis. NGs were basically prepared as described above but included non-protonated DOX in the DMF solution (detailed synthetic conditions in the ESI). Commonly employed DOX-HCl could not be incorporated due to hydrolysis of the NGs under acid conditions. Ideally, the drug would interact with macromolecular hPG and the monomers when injected into the non-solvent, leading to its

entrapment within the crosslinked NG. This methodology allows the production of NG containing an anticancer drug in one single step, thus avoiding tedious post-encapsulation and purification process. In addition, the incorporation of the drug during the nanoprecipitation process enabled higher encapsulation efficiencies. Thus, the maximum amount of DOX that was reached when the drug was post-encapsulated within unloaded NGs was 5% (weight %, data not shown), while values of 10% could be achieved by the one-pot approach.

DOX-loaded NGs were characterized by FT-IR and DLS. DLS showed a slight increase in size (115 nm) and a low PDI (0.12). In the case of the control NGs that lacked one of the responsive moieties, sizes and PDIs varied significantly (Table 1). DOX-loaded NGs were purified using a centrifugal filter device followed by dialysis in PB buffer 10 mM pH 8. After purification, NGs were analysed by size exclusion chromatography using Sephadex G25 gel to verify that there was no free drug. The NGs were freeze-dried and the DOX content was determined by UV-Vis measurements in DMSO/H₂O (9:1) ($\lambda = 503 \text{ nm}$) after performing a calibration curve (Fig. S3). In the case of NGs containing all monomers, DOX quantification can also be performed in H₂O (Fig. S5a). Notably, DOX loading in the different NGs varied significantly. For example, the NG lacking BMADS displayed a much lower drug content. This might be explained by the less compact polymeric network for this NG, which would have facilitated the diffusion of the drug during the purification steps.

Table 1. Features of DOX-loaded NGs.

Nanogel	Size (nm)	PDI	DOX loading (wt %)
All monomers	115	0.12	10%
w/o DMDEA	287	0.4	10%
w/o OEGA	146	0.29	8%
w/o BMADS	186	0.35	7%

In order to prove DOX stability under free radical polymerization environment, free DOX was treated under NG formation conditions, purified, and analysed by HPLC and mass spectrometry. The expected mass ($[\text{M} + \text{Na} + 2\text{H}]^+$: 568.14) was found in the mass spectrum, while HPLC chromatograms revealed the same retention time for treated-DOX, untreated DOX-HCl, and deprotonated untreated-DOX (Fig. S4, ESI).

In vitro DOX release was analysed for the NGs at different pH values and in the presence of the reducing agent DTT. Notably, an accelerated drug release for the NG containing all monomers and crosslinkers was observed at pH 5 in the presence of 20 mM DTT. Thus, approx. 95% of DOX was released after 8 h, while only 20% of free drug could be observed for the same incubation time at pH 8 (Fig. S5b, ESI).

The cytotoxicity and internalization of the NGs in A549 lung-carcinoma cells was then investigated. MTT assays showed an IC₅₀ value of ca. 1 mg/mL for unloaded NGs (Fig. S6a, ESI). However, no effect on cell proliferation and morphology was observed in real time cell analysis (RTCA, Fig. S7, ESI) at a concentration of 0.54 mg/mL, which corresponds to 100 μM DOX in the drug-loaded NGs. Considering the high cytotoxicity of DOX at such concentration, the NGs appear to be suitable drug carrier candidates.

Cell proliferation inhibition of DOX-loaded NGs were studied by RTCA and MTT assays and finally compared to free DOX (Fig. 4, S6b. and S7, ESI). Fig. 4 shows the inhibition of cell proliferation at a concentration of 10 μM DOX (for dose-response curves see Fig. S6b, ESI). DOX-loaded NGs containing all monomers caused a reduction of viability to 27% on average, which was the closest to free DOX (18%). NGs without OEGA, BMADS or DMDEA caused

significantly less reduction, with mean values of 38%, 39% and 33.6%, respectively. When the effect of the DOX-loaded NGs on the morphology and proliferation of cancer cells was analysed in real time, the NGs with all monomers showed again the most similar profile to that of free DOX (Fig. S7, ESI). The NGs lacking any of the responsive moieties were less effective and presented very dissimilar profiles, suggesting that the combination of the different stimuli in the multiresponsive NGs may have a synergistic effect.




Fig. 4. Cell proliferation inhibition of DOX-loaded NGs at 10 μ M (DOX concentration) as determined by MTT assay on A549 cells, (* $p < 0.05$, ** $p < 0.01$). See also Table S2, ESI)

Finally, internalization of the DOX-loaded NGs (all monomers) into A549 cells was studied by confocal laser scanning microscopy (Fig 5 and S8, ESI). After 2 h of incubation, the NGs were accumulated in the endosomes/lysosomes (co-localization with LysoTracker), and some DOX fluorescence could be detected in the cytoplasm.




Fig. 5. Confocal microscopy images of DOX-loaded NGs on A549 cells. Red: DOX, green: LysoTracker green stained lysosomes, yellow: merged colour.

Conclusions

We have developed a simple, reproducible, one-pot synthetic approach that allows the preparation of DOX-loaded multiresponsive NGs based on biocompatible hPG. This strategy combines free radical polymerization, nanoprecipitation, and high-loading drug encapsulation in a single step. The method here described could be applied for the in situ encapsulation of other drugs or bioactive molecules into NGs prepared by polymerization processes. Unloaded NGs were first prepared and their multiresponsive properties were analysed in vitro and compared with the corresponding controls. The NGs showed a high increase in their sizes and PDI in the presence of acidic pH and DTT, which can be exploited for intracellular drug release. DOX-loaded NGs (containing all monomers or lacking any of the responsive moieties) were prepared and their relative performances in cell proliferation inhibition were studied. The different cytotoxicity profiles obtained in MTT assays and RTCA suggest the presence of a synergistic effect for the multiresponsive NGs. Finally, confocal microscopy studies revealed that DOX-loaded NGs were efficiently internalized by A549 cancer cells.

This research was financially supported by a Marie Curie IEF (Project 302717), the ThermoNanogele NanoMatFutur award (13N12561), and the focus area Nanoscale of the FU Berlin.

Notes and references

^aInstitut für Chemie und Biochemie, Freie Universität Berlin, Takustrasse 3, 14195 Berlin, Germany. E-mail: marcelo.calderon@fu-berlin.de

† Electronic Supplementary Information (ESI) available: Experimental section and supplemental figures. See DOI: 10.1039/c000000x/

- O. C. Farokhzad and R. Langer, *Adv. Drug Delivery Rev.*, 2006, **58**, 1456-1459.
- D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, *Nat Nano*, 2007, **2**, 751-760.
- Y. Qiu and K. Park, *Adv. Drug Delivery Rev.*, 2001, **53**, 321-339.
- M. Motornov, Y. Roiter, I. Tokarev and S. Minko, *Prog. Polym. Sci.*, 2010, **35**, 174-211.
- S. Ganta, H. Devalapally, A. Shashiwala and M. Amiji, *J. Control. Release*, 2008, **126**, 187-204.
- N. A. Peppas, J. Z. Hilt, A. Khademhosseini and R. Langer, *Adv. Mater.*, 2006, **18**, 1345-1360.
- J. K. Oh, R. Drumright, D. J. Siegwart and K. Matyjaszewski, *Prog. Polym. Sci.*, 2008, **33**, 448-477.
- M. Asadian-Birjand, A. Sousa-Herves, D. Steinhilber, J. C. Cuggino and M. Calderon, *Curr Med Chem*, 2012, **19**, 5029-5043.
- A. V. Kabanov and S. V. Vinogradov, *Angew. Chem. Int. Ed.*, 2009, **48**, 5418-5429.
- M. H. Smith and L. A. Lyon, *Acc. Chem. Res.*, 2011, 985-993.
- X. Zhang, K. Achazi, D. Steinhilber, F. Kratz, J. Dervede and R. Haag, *J. Control. Release*, 2014, **174**, 209-216.
- D. Steinhilber, M. Witting, X. Zhang, M. Staegemann, F. Paulus, W. Friess, S. Küchler and R. Haag, *J. Control. Release*, 2013, **169**, 289-295.
- M. Giubudagian, M. Asadian-Birjand, D. Steinhilber, K. Achazi, M. Molina and M. Calderon, *Polymer Chemistry*, 2014, **5**, 6909-6913.
- D. Wilms, S.-E. Stiriba and H. Frey, *Acc. Chem. Res.*, 2010, **43**, 129-141.
- M. Calderón, M. A. Quadir, S. K. Sharma and R. Haag, *Adv. Mater.*, 2010, **22**, 190-218.
- R. K. Kainthan and D. E. Brooks, *Biomaterials*, 2007, **28**, 4779-4787.
- M. Schömer, C. Schüll and H. Frey, *J. Polym. Sci., Part A: Polym. Chem.*, 2013, **51**, 995-1019.
- L. Zha, B. Banik and F. Alexis, *Soft Matter*, 2011, **7**, 5908-5916.
- S. Lee, K. Saito, H.-R. Lee, M. J. Lee, Y. Shibasaki, Y. Oishi and B.-S. Kim, *Biomacromolecules*, 2012, **13**, 1190-1196.
- Z.-Y. Qiao, R. Zhang, F.-S. Du, D.-H. Liang and Z.-C. Li, *J. Control. Release*, 2011, **152**, 57-66.
- J. Peng, T. Qi, J. Liao, B. Chu, Q. Yang, W. Li, Y. Qu, F. Luo and Z. Qian, *Biomaterials*, 2013, **34**, 8726-8740.
- S. Mura, J. Nicolas and P. Couvreur, *Nat. Mater.*, 2013, **12**, 991-1003.
- E. Lepeltier, C. Bourgaux and P. Couvreur, *Adv. Drug Delivery Rev.*, 2014, **71**, 86-97.
- Z.-Y. Qiao, F.-S. Du, R. Zhang, D.-H. Liang and Z.-C. Li, *Macromolecules*, 2010, **43**, 6485-6494.
- S. Höfl, L. Zitzler, T. Hellweg, S. Herminghaus and F. Mugele, *Polymer*, 2007, **48**, 245-254.
- G. Liu, Q. Qiu and Z. An, *Polymer Chemistry*, 2012, **3**, 504-513.